A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
Pfizer
Exscientia AI Limited
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Genentech, Inc.
Alnylam Pharmaceuticals
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
UMC Utrecht
Boston Scientific Corporation
Beijing Biotech
Aptamer Sciences, Inc.
AbbVie
Case Comprehensive Cancer Center
Varian, a Siemens Healthineers Company
Assistance Publique - Hôpitaux de Paris
Ankara Etlik City Hospital
University of California, Irvine
Dana-Farber Cancer Institute
Cedars-Sinai Medical Center
Pilatus Biosciences Inc
Essen Biotech
Essen Biotech
Thomas Jefferson University
Seattle Children's Hospital
Angiex, Inc.
New Phase Ltd.
Stanford University
University of Manitoba
Nanjing Sanhome Pharmaceutical, Co., Ltd.
DualityBio Inc.
Grey Wolf Therapeutics
Zhejiang University
Conjupro Biotherapeutics, Inc.
GrandPharma (China) Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
RenJi Hospital
University of Kansas Medical Center
West China Hospital
Myeloid Therapeutics
West China Hospital
RenJi Hospital
Eureka Therapeutics Inc.
University of Texas Southwestern Medical Center
Yonsei University
Duke University
Thomas Jefferson University
VA Office of Research and Development
National Cancer Centre, Singapore